- Home
- TSAT vs LXEO Comparison
TSAT vs LXEO Comparison
Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- LXEO
- Stock Information
- Founded
- TSAT 1969
- LXEO 2017
- Country
- TSAT Canada
- LXEO United States
- Employees
- TSAT N/A
- LXEO N/A
- Industry
- TSAT Metal Fabrications
- LXEO
- Sector
- TSAT Industrials
- LXEO
- Exchange
- TSAT Nasdaq
- LXEO Nasdaq
- Market Cap
- TSAT 233.1M
- LXEO 93.9M
- IPO Year
- TSAT 1996
- LXEO 2023
- Fundamental
- Price
- TSAT $24.53
- LXEO $4.13
- Analyst Decision
- TSAT
- LXEO Strong Buy
- Analyst Count
- TSAT 0
- LXEO 5
- Target Price
- TSAT N/A
- LXEO $16.60
- AVG Volume (30 Days)
- TSAT 143.8K
- LXEO 671.0K
- Earning Date
- TSAT 08-13-2025
- LXEO 08-11-2025
- Dividend Yield
- TSAT N/A
- LXEO N/A
- EPS Growth
- TSAT N/A
- LXEO N/A
- EPS
- TSAT N/A
- LXEO N/A
- Revenue
- TSAT $372,642,710.00
- LXEO N/A
- Revenue This Year
- TSAT N/A
- LXEO N/A
- Revenue Next Year
- TSAT N/A
- LXEO N/A
- P/E Ratio
- TSAT N/A
- LXEO N/A
- Revenue Growth
- TSAT N/A
- LXEO N/A
- 52 Week Low
- TSAT $7.21
- LXEO $1.45
- 52 Week High
- TSAT $26.07
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- TSAT 71.52
- LXEO 58.96
- Support Level
- TSAT $22.35
- LXEO $3.63
- Resistance Level
- TSAT $26.07
- LXEO $4.50
- Average True Range (ATR)
- TSAT 1.73
- LXEO 0.44
- MACD
- TSAT 0.84
- LXEO 0.01
- Stochastic Oscillator
- TSAT 84.58
- LXEO 60.77
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.